NDAORALCAPSULE, EXTENDED RELEASE2 Generics Approved
Approved
Sep 1995
Lifecycle
LOE Approaching
Competitive Pressure
60/100
Data completeness
2/8 — Basic
Drug data last refreshed 3d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TIAZAC is a calcium channel blocker (diltiazem hydrochloride) in extended-release capsule form approved for hypertension treatment. It works by inhibiting calcium ion influx during cardiac and vascular smooth muscle depolarization, causing relaxation of vascular smooth muscle and decreased peripheral vascular resistance. The drug reduces blood pressure primarily through vasodilation with minimal reflex tachycardia.
$0.108MPart D
LOE ApproachingDeclining
As LOE approaches, TIAZAC faces shrinking market opportunity with minimal Part D utilization; brand team likely focused on cost management and retention of legacy patient populations rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on TIAZAC offers experience in late-stage product management and defensive strategy within a mature, declining brand. Career growth is constrained by LOE timeline and generic competition; best suited for professionals seeking to develop crisis management, managed care negotiation, and product lifecycle extension skills rather than growth marketing experience.
Brand Manager
Worked on TIAZAC at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.